PRRUF
IMMUTEP Ltd
$0.0500
0.00%
No data for this timeframe.
Vol
SEC Reports2
Recent Activity
May 1, 2026
SEC
Immutep reported discontinuation of its lead TACTI-004 Phase III trial for eftilagimod alfa in first-line non-small cell
6-K — Impact 8/10
Apr 1, 2026
SEC
Howard Russell J, an insider at IMMUTEP Ltd, filed a Form 3 disclosing beneficial ownership of 1,717,977 ordinary shares
3 — Impact 3/10
Analyst Ratings
1Strong Buy
3Buy
4Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 50% buy across 8 analysts — 1 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 87.4% | — |
| Next FY 2027-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -86.4% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| May 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| Apr 1, 2026 | 1 | 3 | 4 | 0 | 0 | 50% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 22, 2026
Clinical Trial
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Phase Phase 2 — COMPLETED